The effects of the tumor necrosis factor (TNF), and a second pleiotropic cytokine interferon-gamma (IFN), were examined in a line of human myeloblastic leukemia cells (ML-1). By itself, TNF causes ML-1 to differentiate along the monocytic pathway. The cells exhibit an increase in Fc receptors and ac
Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor
β Scribed by Joan H. Schiller; Patricia L. Witt; Barry Storer; Dona Alberti; Mary Beth Tombes; Rhoda Arzoomanian; Raymond R. Brown; Richard A. Proctor; Stephan D. Voss; David R. Spriggs; Donald L Trump; Ernest C. Borden
- Publisher
- John Wiley and Sons
- Year
- 1992
- Tongue
- English
- Weight
- 894 KB
- Volume
- 69
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The combination of retinoic acid or tumor necrosis factor for TNF-alpha. IFN-gamma and TNF-alpha were diluted in alpha FNF-alpha) with interferon gamma (IFN-gamma) re-minimum essential medium (MEM) containing 15 % fetal bosulted in a Synergistic amplification Of the anti-proliferative vine Semm (FBS
The anti-tumor activity of partially purified tumor necrosis factor (TNF) was analysed in combination with chemotherapeutic drugs against intradermally transplanted Meth A sarcoma. Tumors were allowed to grow until they reached an average diameter of about 8 mm. TNF was given once i.v. (16,000 units
## Background: Isolated limb perfusion (ilp) with tumor necrosis factor alpha (tnf alpha) +/-interferon gamma (ifn gamma) and melphalan in patients with primarily irresectable soft tissue sarcoma is promising in terms of tumor regression and limb salvage. however, the feasibility of radiotherapy in